I am often accused of being a glass half empty Yorkshireman and never sufficiently positive. But I think MS can learn from Lupus and it’s little cousin called neuromyelitis optica or historically Devics multiple sclerosis. CAR-T therapy where you make T cells target something else using a chimeric antigen receptor. Chimeric because the antigen receptor is part T cells and delivers the T cells activation signal and part B cells as it is an antibody that gives specificity and targeting. The current major targets are CD19 to kill most B cells and we know this works in MS already in a few people where it has been done and we know that the cells get into the brain unlike antibodies. Another target is B cells maturation antigen on antibody producing cells. The way you get a CAR-T is you infect the T cells grow them in a test tube. You have to immunosuppress the individual. Now they have developed a way to do the infection in the body and this a technological advantage. They say NMO is driven by a certain type of cell the next thing is to target the cells that drive the disease. So you could kill aquaporin four specific cells you can kill EBV
Source: multiple-sclerosis-research.org